A case of lymphocytic myocarditis in a patient treated with an immune checkpoint inhibitor, a recent class of chemotherapy agents

Autor: Tatiana Duarte, Cátia Costa, Sara Gonçalves, Luís Raposo, António Ferreira, Catarina Albuquerque, Nuno Vau, Rui Caria

Publikováno v: Revista Portuguesa de Cardiologia, Vol 41, Iss 12, Pp 1047-1051 (2022)

Chemotherapy-associated cardiotoxicity is a common adverse event. Immune checkpoint inhibitors (ICI) – a new class of monoclonal antibodies – have revolutionized the management of various diseases. Their use is expected to increase in the near fu

Externí odkaz: https://doaj.org/article/fdac67f0b87f4234a9715c93bcf88bb3

Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward

Autor: Andreia Bilé-Silva, Antonio Lopez-Beltran, Ana Blanca, Fernando Lopez-Rios, Enrique Gómez-Gómez, Alessia Cimadamore, Rodolfo Montironi, Nuno Vau, Liang Cheng

Publikováno v: Expert Opinion on Biological Therapy. 23:407-418

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0df7a5c8ace4e1bc69d7a60d58ad7b55
https://doi.org/10.1080/14712598.2023.2201371

Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)

Autor: Matteo Santoni, Francesco Massari, Zin W. Myint, Roberto Iacovelli, Martin Pichler, Umberto Basso, Jindrich Kopecky, Jakub Kucharz, Sebastiano Buti, Alessia Salfi, Thomas Büttner, Ugo De Giorgi, Ravindran Kanesvaran, Ondřej Fiala, Enrique Grande, Paolo Andrea Zucali, Giuseppe Fornarini, Maria T Bourlon, Sarah Scagliarini, Javier Molina-Cerrillo, Gaetano Aurilio, Marc R Matrana, Renate Pichler, Carlo Cattrini, Tomas Büchler, Emmanuel Seront, Fabio Calabrò, Alvaro Pinto, Rossana Berardi, Anca Zgura, Giulia Mammone, Jawaher Ansari, Francesco Atzori, Rita Chiari, Roubini Zakopoulou, Orazio Caffo, Giuseppe Procopio, Maria Bassanelli, Ilaria Zampiva, Carlo Messina, Zsófia Küronya, Alessandra Mosca, Dipen Bhuva, Nuno Vau, Lorena Incorvaia, Sara Elena Rebuzzi, Giandomenico Roviello, Ignacio Ortego Zabalza, Alessandro Rizzo, Veronica Mollica, Ilaria Catalini, Fernando Sabino M. Monteiro, Rodolfo Montironi, Nicola Battelli, Mimma Rizzo, Camillo Porta

Background: Obesity has been associated with improved response to immunotherapy in cancer patients. We investigated the role of body mass index (BMI) in patients from the ARON-1 study (NCT05287464) treated by dual immuno-oncology agents (IO+IO) or a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12f357fc06502ee653e2380faa5136fd
https://hdl.handle.net/10447/587700

Immune checkpoint inhibitors for the treatment of bladder cancer

Autor: Rodolfo Montironi, Marina Scarpelli, Ana Blanca, Nuno Vau, Francesco Massari, Liang Cheng, Alessia Cimadamore, Antonio Lopez-Beltran

Publikováno v: Cancers, Vol 13, Iss 131, p 131 (2021)
Cancers 13(1), 131 (2021)
Helvia: Repositorio Institucional de la Universidad de Córdoba
Universidad de Córdoba
Cancers
Helvia. Repositorio Institucional de la Universidad de Córdoba
Universidad de Cantabria (UC)

Simple Summary In this review, we examined relevant clinical trial results with immune checkpoint inhibitors in patients with metastatic urothelial cancer. We also focused on the potential of immunotherapy in the adjuvant and neoadjuvant setting or a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e43df31ac1e76f80af64ebab6f7a2416
https://hdl.handle.net/11390/1242925

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors

Autor: Alessia Cimadamore, Camillo Porta, Giacomo Cartenì, Paolo Andrea Zucali, Cinzia Ortega, Roberto Iacovelli, Matteo Santoni, Daniele Santini, Alessandra Mosca, Erin Pierce, Marc R. Matrana, Elena Verzoni, Orazio Caffo, Michele Milella, Rodolfo Montironi, Sebastiano Buti, Jeffrey Graham, Sara Merler, Francesco Carrozza, Sergio Bracarda, Marina Scarpelli, Umberto Basso, Francesco Massari, Francesco Piva, Liang Cheng, Vittorio Paolucci, Angelo Martignetti, Franco Morelli, Cristina Masini, Fabio Calabrò, Giuseppe Fornarini, Sarah Scagliarini, Lorena Incorvaia, Nuno Vau, Mimma Rizzo, Francesco Atzori, Alain Gelibter, Riccardo Ricotta, Antonio Lopez-Beltran, Maria Giuseppa Vitale, Ugo De Giorgi, Simon J. Crabb, Giulia Sorgentoni, Pierangela Sepe, Luca Galli, Giuseppe Procopio, Daniel Y. Heng, Alessandro Conti, Nicola Battelli

Publikováno v: Cancers
Volume 12
Issue 1
Cancers, Vol 12, Iss 1, p 84 (2019)

Cabozantinib is approved for the treatment of renal cell carcinoma (RCC). However, prognostic factors are still lacking in this context. The aim of this study was to evaluate prognostic factors in RCC patients treated with second- or third-line caboz

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cb195a8a2a20780d892ff3b9eccb944